Arialys Therapeutics announces U.S. FDA fast track designation for ART5803, the first precision therapeutic candidate in development for the treatment of anti-nmda receptor encephalitis Business Wire (Press Release) 2d Business Wire (Press Release) 2d
Proteina shares surge 19% after AI antibody option deal with Samsung Bioepis Korea Biomedical Review 2d Korea Biomedical Review 2d
Former Astrazeneca employee settles insider trading charges BioWorld 12h BioWorld 12h Article paywall
Maia reports positive efficacy results from Phase II trial for NSCLC Clinical Trials Arena 2d Clinical Trials Arena 2d
Ionis, Az shares down on unexpected Wainua flop in cardiomyopathy BioWorld 1d BioWorld 1d Article paywall
GPC Targeting With Glymphatic Delivery Could Be New Strategy in HD, Other Neurologic Diseases Rare Disease Advisor 22:37 Fri, 10 Jul
Gilead’s Biggest Buys Balance Drug Candidate Needs With Platform Desires Scrip Pharma Intelligence 22:35 Fri, 10 Jul
Danaher-Masimo close caps med tech’s strongest first-half since 2022 BioWorld 21:12 Fri, 10 Jul Article paywall
Q32 Bio to Report 36-Week Topline Results from Part B of signal-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 PR Newswire (Press Release) 21:08 Fri, 10 Jul
Hlb, Hengrui receive third US FDA rejection on liver cancer combo BioWorld 19:43 Fri, 10 Jul Article paywall
Former Astrazeneca employee settles insider trading charges BioWorld 19:29 Fri, 10 Jul Article paywall
Mhra adds economic growth to its drug and device regulation remit BioWorld 19:29 Fri, 10 Jul Article paywall